EGFR and neoplasm: In contrast, the addition of the EGFR family inhibitor Poziotinib to RMC‐6236 completely prevented tumor outgrowth over the 80‐day investigation period, highlighting the significantly enhanced efficacy of the combination therapy (Figure 4k).